CD8 T Cells
The harnessing and purification of CD8+ T cells as a novel therapy for neoplastic diseases is a recent innovation. With improvements in the understanding of T cell biology, the identification of specific subsets of CD8+ T cells has been shown to be superior at suppressing tumor activity both in vitro and in vivo. Recent clinical trials using both purified tumor infiltrating lymphocytes (TILs) as well as the novel chimeric antigen receptor T cells (CAR T cells) have shown great promise in the treatment of a variety of neoplasias including melanoma, and leukemias. Many clinical trials are now ongoing to elucidate the potential of these new therapies.
KeywordsAdoptive cell therapy CD8+ T cells Chimeric antigen T-cell receptor (CAR) T cells Cytoreductive therapy Effector T cells Naïve T cells Programmed-death receptor ligand-1 (PDL-1)
- Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology. 7th ed. Philadelphia: Elsevier/Saunders; 2012.Google Scholar
- Brentjens RJ, Curran KJ. Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. Hematol/Educ Prog Am Soc Hematol Am Soc Hematol. 2012;2012:143–51.Google Scholar
- Kochenderfer JN, Rosenberg SA. Treating B cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev. 2013;10(5):267–76.Google Scholar
- Murphy K, Travers P, Walport M, Janeway C. Janeway’s immunobiology. 8th ed. New York: Garland Science; 2012.Google Scholar
- Restifo NP, Robbins PF, Rosenberg SA. Tumor immunology. In: Paul WE, editor. Fundamental immunology. 6th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2008. p. 1489–522.Google Scholar